The European Qualified Person: Legal Accountability, Quality Leadership, and AI Integration in Modern Pharmaceutical Manufacturing: Navigating Complex Therapies and AI-Supported Oversight to Safeguard Patient Safety
Clinical Snapshot
PICO Framework
| P — Population | European Qualified Persons (QPs) in pharmaceutical manufacturing |
| I — Intervention | AI integration within Human-in-the-Loop (HITL) frameworks for quality oversight |
| C — Comparator | Traditional oversight methods without AI support |
| O — Outcomes | Enhanced decision-making, regulatory compliance, patient safety, and batch release processes |
Bottom Line
This narrative review explores the integration of artificial intelligence technologies into European pharmaceutical quality assurance, specifically focusing on Qualified Person responsibilities. While the topic is highly relevant to modern pharmaceutical manufacturing, the review lacks systematic methodology and quantitative evidence. The proposed Human-in-the-Loop framework appears conceptually sound for maintaining human oversight while leveraging technological capabilities. However, without empirical data on implementation outcomes, cost-effectiveness, or comparative studies, the clinical utility remains theoretical. Australian pharmaceutical professionals should consider these concepts within the TGA regulatory framework, recognizing that substantial infrastructure investment and training would be required for implementation. The review serves as a useful starting point for understanding emerging trends but should not be considered definitive guidance for practice changes.
Key Findings
Effect Size: Not quantified - conceptual framework
Primary Outcome: Framework for AI integration in QP oversight while maintaining human accountability
Nnt Or Sensitivity: Not applicable - qualitative review
Clinical Application
Moderate - requires significant investment in technology infrastructure and training Relevant to TGA manufacturing standards and quality assurance frameworks, though European-specific regulations may not directly apply Pharmaceutical quality professionals, regulatory affairs specialists, and manufacturing leaders
Abstract
The European Qualified Person (QP) holds unique legal responsibility for certifying batch release, ensuring patient safety, and maintaining regulatory compliance. Modern pharmaceutical manufacturing-especially in biologics, advanced therapy medicinal products (ATMPs), and personalized medicines-generates complex, multi-site, data-rich environments that challenge traditional oversight. Artificial Intelligence (AI) offers predictive analytics, anomaly detection, and trend recognition to support decision-making but cannot currently replace the QP's scientific judgment or legal accountability. The forthcoming Annex 22 introduces Human-in-the-Loop (HITL) frameworks that embed human oversight within AI-supported processes, aligning technological advancement with regulatory control. This review explores evolving QP responsibilities, core and emerging competencies, AI integration within Quality Risk Management (QRM) and Good Manufacturing Practice (GMP) frameworks, and ethical considerations, illustrated with practical case studies. By developing AI literacy and applying HITL oversight, QPs can more effectively translate technological potential into transparent, science-based, and patient-centered batch-release decisions.
References
- 1.Stassen, M. (2026). The European Qualified Person: Legal Accountability, Quality Leadership, and AI Integration in Modern Pharmaceutical Manufacturing: Navigating Complex Therapies and AI-Supported Oversight to Safeguard Patient Safety. PDA Journal of Pharmaceutical Science and Technology. https://doi.org/10.5731/pdajpst.2025-000067.1
Related Research
Journal of pharmacokinetics and pharmacodynamics
Diffusion models for virtual populations and pharmacometric simulations
1 Aug 2026
Journal of chemical information and modeling
Reinforcement Learning-Driven Multiproperty Optimization in Molecular Design Using Multicontext Transcriptome Data
29 July 2026
Journal of computer-aided molecular design
Artificial intelligence in impurity prediction: current landscape, challenges, and future directions
23 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service